INTREXON CORP
CIK 1356090 · SVP, Consumer Sector · last filed 2018-09-28
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$835
Companies
7
Total Filings
36
Lifetime Open-Market Net
$174.12M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Alaunos Therapeutics, Inc. (ZIOP) Delisted | 10%+ Owner | 198,259 | $0.87 | $171.6K | $80.18M | 24 | 2018-09-28 |
| Fibrocell Science, Inc. (FCSC) Delisted | 10%+ Owner | 1,154,725 | — | — | $29.20M | 3 | 2017-12-13 |
| SOLIGENIX, INC. (SNGXW) Delisted | 10%+ Owner | 101,171 | $0.01 | $911 | -$1.00M | 1 | 2017-05-08 |
| AQB | 10%+ Owner | 539 | $0.92 | $496 | $50.02M | 1 | 2017-01-20 |
| Armata Pharmaceuticals, Inc. (APHB) Delisted | 10%+ Owner | 48,155 | — | — | -$168.8K | 2 | 2016-12-29 |
| PRECIGEN, INC. (XON) Delisted | SVP, Consumer Sector | — | — | — | $0 | 2 | 2016-01-26 |
| OGEN | 10%+ Owner | 679 | $0.50 | $340 | $15.89M | 2 | 2015-12-03 |
Recent Filings · Page 3 of 4
36 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2016-07-06 | Alaunos Therapeutics, Inc. (ZIOP) Delisted | Buy (P) | — | $0 | EDGAR |
| 2016-01-26 | PRECIGEN, INC. (XON) Delisted | — | — | $0 | EDGAR |
| 2016-01-11 | PRECIGEN, INC. (XON) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-12-03 | OGEN | Conv (C) | +6,762,008 | $10.14M | EDGAR |
| 2015-03-18 | — | Buy (P) | +27,878,784 | $4.60M | |
| 2015-02-10 | Alaunos Therapeutics, Inc. (ZIOP) Delisted | Buy (P) | +2,880,000 | $25.20M | EDGAR |
| 2014-01-28 | Fibrocell Science, Inc. (FCSC) Delisted | Buy (P) | +2,049,180 | $10.00M | EDGAR |
| 2014-01-03 | Alaunos Therapeutics, Inc. (ZIOP) Delisted | Grant (A) | +37,636 | $0 | EDGAR |
| 2013-10-02 | OGEN | Buy (P) | +5,297,020 | $15.89M | EDGAR |
| 2013-07-30 | Fibrocell Science, Inc. (FCSC) Delisted | Buy (P) | +2,487,562 | $15.00M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.